Latest Innovation News

Blue Energy Limited reports steady progress in its Sapphire Pilot gas production despite operational interruptions and ongoing environmental authority appeals, while advancing seismic exploration in the Northern Territory.

Papyrus Australia has taken significant strides in Q4 2024, signing a joint venture terms sheet in Vietnam, appointing new board members, and securing R&D tax incentives, positioning itself for expanded commercialization.

Audio Pixels Holdings Limited reports significant technical progress in its Digital Sound Reconstruction technology and secures additional funding through convertible notes, while continuing to navigate ASX suspension challenges.

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.

Dotz Nano Limited has landed its first commercial order for DotzShield in the U.S. and made significant strides in carbon capture technology development, including a new sorbent for Direct Air Capture and a strategic collaboration with Bar-Ilan University.

Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.

Structural Monitoring Systems plc has raised $8.7 million and implemented a major cost restructuring, positioning itself for profitable growth with strong sales momentum in its avionics and sensor technology segments.

Nova Eye Medical has completed a $6.6 million placement to fund growth initiatives, supported by strong global sales growth and a major shareholder commitment. The capital raise aims to bolster sales teams and product development as the company targets profitability in its glaucoma division.

Aeris Environmental Ltd reported a 5% revenue increase to $766,000 in the December 2024 quarter, driven by strong margins and momentum in its AerisTech joint venture. The company’s expanding customer base and strategic partnerships signal promising growth in smart building solutions and consumables.

Nova Eye Medical reports a robust 39% increase in global sales driven by strong U.S. market demand and secures $6.6 million in fresh capital to fuel expansion and product development.

Australian Bond Exchange Holdings reports a halving of its operating cash flow shortfall in Q2 FY25, driven by a successful cost reduction program and the launch of a new market-linked security. The company is accelerating its AI initiatives to enhance compliance and transaction efficiency.